Research Analysts Issue Forecasts for Zoetis Q3 Earnings

Zoetis Inc. (NYSE:ZTS) – Zacks Research lowered their Q3 2025 EPS estimates for Zoetis in a research report issued on Wednesday, October 23rd. Zacks Research analyst E. Bagri now anticipates that the company will earn $1.61 per share for the quarter, down from their previous forecast of $1.63. The consensus estimate for Zoetis’ current full-year earnings is $5.83 per share.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter in the prior year, the company posted $1.41 earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year.

A number of other equities research analysts have also commented on the company. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Price Performance

Shares of NYSE ZTS opened at $180.01 on Friday. The business’s 50 day moving average price is $189.18 and its 200 day moving average price is $177.61. The firm has a market cap of $82.14 billion, a P/E ratio of 34.68, a P/E/G ratio of 2.94 and a beta of 0.89. Zoetis has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ZTS. Webster Bank N. A. raised its stake in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares during the period. Quarry LP raised its stake in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the period. LRI Investments LLC acquired a new position in shares of Zoetis during the 1st quarter worth approximately $43,000. Fortitude Family Office LLC raised its stake in shares of Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after buying an additional 222 shares during the period. Finally, Central Valley Advisors LLC acquired a new position in shares of Zoetis during the 2nd quarter worth approximately $49,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.96%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is 33.14%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.